Vaccine Info

MVA-BN-RSV Vaccine

MVA-BN-RSV Vaccine Description

MVA-BN-RSV vaccine incorporates five different RSV antigens to stimulate a broad immune response against both RSV subtypes (A and B), thus mimicking the immune response observed following a natural response to an RSV infection.

MVA-BN-RSV Vaccine Indication

MVA-BN-RSV Vaccine is indicated to prevent RSV (respiratory syncytial virus). RSV is highly infectious and the most common cause of lower respiratory tract infection in infants and children worldwide, resulting in a high number of hospitalizations. RSV infections are also a serious health concern in the elderly and in adults with cardiopulmonary disease.

MVA-BN-RSV Vaccine News

August 8, 2018: Bavarian Nordic announced positive data from the extension study of its Phase 2 study investigating the safety and immune responses of its universal RSV vaccine, MVA-BN® RSV in an older adult population. 

December 14, 2016: Bavarian Nordic announced that it has completed enrollment of 400 subjects in a Phase 2 clinical study of MVA-BN® RSV, a novel, broad-spectrum, vaccine candidate against RSV (respiratory syncytial virus). 

September 29, 2016: Bavarian Nordic announced the presentation of data from a Phase 1 study of its novel, broad-spectrum RSV (respiratory syncytial virus) vaccine candidate, MVA-BN RSV®.


MVA-BN-RSV Vaccine Clinical Trials

Clinical Trial NCT02873286:  RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults

This phase 2 clinical study investigated a multivalent RSV vaccine (MVA-BN®-RSV) designed to induce broad antibody and cellular immune responses by encoding RSV surface proteins F, G (for both A and B subtypes), and internal antigens (M2, N).

This study evaluated the immune response in adults ≥55 years to identify the optimal MVA-BN-RSV dose and vaccination schedule.

A single dose increased the levels of neutralizing (PRNT to RSV A and B) and total (IgG and IgA ELISA) antibodies (1.6 to 3.4-fold increase from baseline) and induced a broad Th1-biased cellular immune response (IFN-γ ELISPOT) to all 5 vaccine inserts (5.4 to 9.7-fold increases).

Antibody responses remained above baseline for 6 months.

A 12-month booster dose elicited a booster effect in antibody and T cell responses (up to 2.8-fold from pre-boost levels). No drug-related serious adverse events were reported